Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$0.39 - $0.71 $99,095 - $180,403
254,090 Added 86.92%
546,422 $229,000
Q4 2022

Feb 14, 2023

SELL
$0.33 - $10.44 $28,509 - $901,932
-86,392 Reduced 22.81%
292,332 $116,000
Q3 2022

Nov 15, 2022

BUY
$0.92 - $11.16 $348,426 - $4.23 Million
378,724 New
378,724 $322,000
Q1 2022

May 16, 2022

SELL
$1.06 - $2.1 $208,903 - $413,865
-197,079 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$2.05 - $3.2 $151,749 - $236,876
-74,024 Reduced 27.3%
197,079 $404,000
Q2 2021

Aug 16, 2021

SELL
$2.57 - $4.85 $1.69 Million - $3.18 Million
-656,004 Reduced 70.76%
271,103 $1.1 Million
Q1 2021

May 17, 2021

BUY
$1.9 - $2.82 $101,625 - $150,833
53,487 Added 6.12%
927,107 $2.29 Million
Q4 2020

Feb 16, 2021

BUY
$1.15 - $2.4 $591,807 - $1.24 Million
514,615 Added 143.34%
873,620 $1.86 Million
Q3 2020

Nov 16, 2020

BUY
$1.11 - $1.68 $370,747 - $561,131
334,007 Added 1336.13%
359,005 $434,000
Q2 2020

Aug 17, 2020

BUY
$1.69 - $4.2 $42,246 - $104,991
24,998 New
24,998 $43,000
Q1 2019

May 14, 2019

SELL
$2.79 - $4.09 $47,988 - $70,348
-17,200 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$3.23 - $7.01 $151,910 - $329,687
-47,031 Reduced 73.22%
17,200 $58,000
Q3 2018

Nov 14, 2018

SELL
$6.86 - $9.97 $650,732 - $945,744
-94,859 Reduced 59.63%
64,231 $466,000
Q2 2018

Aug 14, 2018

BUY
$2.88 - $8.67 $4,320 - $13,005
1,500 Added 0.95%
159,090 $1.1 Million
Q1 2018

May 15, 2018

BUY
$2.92 - $3.81 $28,616 - $37,338
9,800 Added 6.63%
157,590 $470,000
Q4 2017

Feb 13, 2018

SELL
$2.99 - $4.85 $37,674 - $61,109
-12,600 Reduced 7.86%
147,790 $454,000
Q3 2017

Nov 14, 2017

SELL
$3.01 - $5.41 $189,329 - $340,289
-62,900 Reduced 28.17%
160,390 $754,000
Q2 2017

Nov 09, 2017

BUY
N/A
223,290
223,290 $487,000

Others Institutions Holding VSTM

About Verastem, Inc.


  • Ticker VSTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 210,000,000
  • Market Cap $796M
  • Description
  • Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...
More about VSTM
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.